Irbesartan Zentiva

Irbesartan, the active ingredient in Irbesartan Zentiva, is an angiotensin II receptor blocker (ARB) presented as an oral tablet for oral use. It is employed to lower high blood pressure and to protect kidney function in patients with diabetic kidney disease. GNH USA supplies Irbesartan Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Irbesartan acts on the renin‑angiotensin‑aldosterone system to manage cardiovascular and renal conditions. - Hypertension: lowers systolic and diastolic blood pressure to reduce cardiovascular risk. - Diabetic nephropathy: slows progression of kidney damage in patients with type 2 diabetes. - Proteinuria in diabetic kidney disease: reduces urinary protein excretion, supporting renal preservation.

Common Side Effects: - Dizziness: sensation of light‑headedness, especially after standing. - Headache: mild to moderate pain in the head region. - Fatigue: feeling unusually tired or weak. - Nausea: upset stomach or urge to vomit.

Serious or Rare Side Effects: - Angioedema: swelling of face, lips, tongue, or throat that may impair breathing. - Hyperkalemia: elevated blood potassium levels that can affect heart rhythm. - Acute renal failure: sudden loss of kidney function requiring medical attention.

Irbesartan should be used with careful clinical monitoring. - Blood pressure monitoring: check regularly to ensure therapeutic control. - Renal function assessment: evaluate serum creatinine and eGFR before and during therapy. - Serum potassium: monitor for hyperkalemia, especially with potassium‑sparing agents. - Hepatic impairment: use cautiously; dose adjustment may be required. - Pregnancy: avoid use; potential fetal harm is unknown. - Store at ambient temperature: keep in the original pack, protect from moisture.

Irbesartan can interact with several medicines, requiring attention to avoid adverse outcomes. Major Interactions (Avoid): - Aliskiren (in diabetic patients): combined use may increase renal risk. - Dual ARB/ACE inhibitor therapy: heightened risk of hypotension and kidney injury. - Potassium‑sparing diuretics: may cause dangerous hyperkalemia. Moderate Interactions (Monitor Closely): - Lithium: increased lithium levels, monitor serum concentrations. - Rifampin: may reduce irbesartan plasma concentrations, adjust dose if needed. - NSAIDs: can diminish antihypertensive effect and impair renal function.